REMODULIN Support Materials

To support your educational needs on REMODULIN® (treprostinil) Injection, there are a number of printed materials available to you. Please be sure to contact your REMODULIN representative to receive or replenish a supply of these pieces. Here you can view and download PDF files of the printed patient materials available.

Flip Chart

This 24-page laminated flip chart is designed to support your educational efforts in the office. It features simple graphics and easy-to-understand descriptions for your patients to follow along. Intended as a talking piece for you to educate your patients on pulmonary arterial hypertension (PAH) and infused prostacyclin, it features an English side and a Spanish side as well as clearly marked topic tabs.

Patient Brochure

This 24-page brochure gives an overview of PAH and the effects it has on the body, as well as an introduction to REMODULIN. It is a good introduction to REMODULIN for your patients and serves as an ideal take-home piece to support the flip chart.

Pocket Guide

This conveniently sized reference guide outlines the treatment goals and an algorithm for managing PAH in high- and low-risk patients. Adapted from a paper by McLaughlin and McGoon,* it also features information on determining patient risk.
*McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-1431.

Reimbursement Flashcard

This fold-out flashcard reference contains useful information on how to streamline product reimbursement, such as diagnostic test results needed and functional classification. Also included is information on REMODULIN distributors and the various specialty pharmacy services and support resources available such as patient assessment, support, discharge planning, hotline access, pump selection, and drug monitoring.

Specialty Pharmacy Service Offerings

  • All third-party reimbursement management
    • De novo patients
    • Patients transitioning from other PAH therapies
  • Patient assessment and evaluation
  • Pre-teaching
    • In home, hospital, or clinic
  • Coordination of services
  • Discharge planning support
  • Hotline access
    • Functions
    • Limitations
    • Service values

Continuous Specialty Pharmacy Support

  • PAH pump selection
  • Dosing sheets
  • Infusion site pain management support
  • Regular communication updates
    • Weekly or monthly, based on patient status
  • Drug monitoring
    • Efficacy
    • Adverse events
    • Drug interactions
  • Patient conviction and compliance with REMODULIN therapy

Site Pain Management Flashcard

This useful flashcard provides detailed information on helping to manage the pain and inflammation of subcutaneous (SC) continuous drug infusion. Included are reminders on managing patients' expectations, information on injection site pain and administration site selection, and a host of pain-management techniques that others have found useful.
Pain Management Flashcard (PDF)

Full Prescribing Information

REMODULIN® (treprostinil) Injection

Indication

REMODULIN is indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who are intolerant of the subcutaneous route, or in whom these risks are considered warranted.

In patients with PAH requiring transition from Flolan® (epoprostenol sodium), REMODULIN is indicated to diminish the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.

Important Safety Information:

Chronic intravenous infusions of REMODULIN are delivered using an indwelling central venous catheter. This route is associated with the risk of blood stream infections (BSI) and sepsis, which may be fatal. Therefore, continuous subcutaneous infusion is the preferred mode of administration. REMODULIN should be used only by clinicians experienced in the diagnosis and treatment of PAH. REMODULIN is a potent pulmonary and systemic vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure. REMODULIN inhibits platelet aggregation and therefore, may increase the risk of bleeding, particularly in patients on anticoagulants. REMODULIN dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn. Initiation of REMODULIN must be performed in a setting with adequate personnel and equipment for physiological monitoring and emergency care. Therapy with REMODULIN may be used for prolonged periods, and the patient’s ability to administer REMODULIN and care for an infusion system should be carefully considered. REMODULIN dosage should be increased for lack of improvement in, or worsening of, symptoms and it should be decreased for excessive pharmacologic effects or for unacceptable infusion site symptoms. Abrupt withdrawal or sudden large reductions in dosage of REMODULIN may result in worsening of PAH symptoms and should be avoided. Caution should be used in patients with hepatic or renal insufficiency.

The most common side effects of REMODULIN included those related to the method of infusion. For subcutaneous infusion, infusion site pain and infusion site reaction (redness and swelling) occurred in the majority of patients. These symptoms were often severe and could lead to treatment with narcotics or discontinuation of REMODULIN. For intravenous infusion, line infections, sepsis, arm swelling, tingling sensations, bruising, and pain were most common. General side effects (>5% more than placebo) were diarrhea, jaw pain, vasodilatation, and edema.

For more information about REMODULIN, please see the Full Prescribing Information.